Evidence map›Paper›PMID 38988046›Full record

ArticleACS applied materials & interfaces2024

Virus-Shaped Mesoporous Silica Nanostars to Improve the Transport of Drugs across the Blood-Brain Barrier.

Alessandra Pinna, Ieva Ragaisyte, William Morton, Stefano Angioletti-Uberti, Alizé Proust, Rocco D'Antuono, Chak Hon Luk, Maximiliano G Gutierrez, Maddalena Cerrone, Katalin A Wilkinson and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alessandra PinnaSchool of Veterinary Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, U.K.ORCID 0009-0001-4467-8484
Ieva RagaisyteDepartment of Materials, Imperial College London, SW7 2AZ London, U.K.
William MortonDepartment of Materials, Imperial College London, SW7 2AZ London, U.K.ORCID 0000-0002-2584-8548
Stefano Angioletti-UbertiDepartment of Materials, Imperial College London, SW7 2AZ London, U.K.
Alizé ProustThe Francis Crick Institute, NW1 1AT London, U.K.
Rocco D'AntuonoCrick Advanced Light Microscopy STP, The Francis Crick Institute, NW1 1AT London, U.K.
Chak Hon LukThe Francis Crick Institute, NW1 1AT London, U.K.
Maximiliano G GutierrezThe Francis Crick Institute, NW1 1AT London, U.K.ORCID 0000-0003-3199-0337
Maddalena CerroneThe Francis Crick Institute, NW1 1AT London, U.K.
Katalin A WilkinsonThe Francis Crick Institute, NW1 1AT London, U.K.
Ali A MohammedDyson School of Design Engineering, Imperial College London, SW7 2AZ London, U.K.
Catriona M McGilveryDepartment of Materials, Imperial College London, SW7 2AZ London, U.K.ORCID 0000-0002-4849-0251
Alejandro Suárez-BonnetThe Francis Crick Institute, NW1 1AT London, U.K.
Matthew ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, 111 Ideation Way, Nutley, New Jersey 07110, United States.
Martin GengenbacherCenter for Discovery and Innovation, Hackensack Meridian Health, 111 Ideation Way, Nutley, New Jersey 07110, United States.ORCID 0000-0002-0208-5920
Robert J WilkinsonThe Francis Crick Institute, NW1 1AT London, U.K.
Alexandra E PorterDepartment of Materials, Imperial College London, SW7 2AZ London, U.K.

Funding

Translational approaches to improve understanding and outcome in Tuberculous meningitisR01AI145436 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI GENGENBACHER, MARTIN ALFONS, LAI, RACHEL PEI JEN · 2020 to 2024
$3.6M
Cancer Research UK CC2112NIAID NIH HHS R01 AI145436Wellcome Trust CC2112
6 · The paper itself

Abstract

Conditions affecting the brain are the second leading cause of death globally. One of the main challenges for drugs targeting brain diseases is passing the blood-brain barrier (BBB). Here, the effectiveness of mesoporous silica nanostars (MSiNSs) with two different spike lengths to cross an

Indexed as

Blood-Brain BarrierSilicon DioxideAnimalsBiological TransportDrug CarriersDrug Delivery SystemsHumansLipid BilayersMolecular Dynamics SimulationNanoparticlesPorosityDrug CarriersLipid BilayersSilicon Dioxideblood–brain barrier modelbrain diseasesmesoporous silica nanoparticlemolecular dynamics simulationnanostar

Identifiers

PMID38988046
PMCPMC11284754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.